These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20009526)

  • 1. Current status of Plasmodium vivax vaccine.
    Arévalo-Herrera M; Chitnis C; Herrera S
    Hum Vaccin; 2010 Jan; 6(1):124-32. PubMed ID: 20009526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the search for a Plasmodium vivax vaccine.
    Herrera S; Corradin G; Arévalo-Herrera M
    Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmodium vivax malaria vaccines: why are we where we are?
    Reyes-Sandoval A; Bachmann MF
    Hum Vaccin Immunother; 2013 Dec; 9(12):2558-65. PubMed ID: 23978931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines against Plasmodium vivax: a research challenge.
    Patarroyo MA; Calderón D; Moreno-Pérez DA
    Expert Rev Vaccines; 2012 Oct; 11(10):1249-60. PubMed ID: 23176656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses.
    White M; Amino R; Mueller I
    Trends Parasitol; 2017 Apr; 33(4):260-263. PubMed ID: 28077251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platform for Plasmodium vivax vaccine discovery and development.
    Valencia SH; Rodríguez DC; Acero DL; Ocampo V; Arévalo-Herrera M
    Mem Inst Oswaldo Cruz; 2011 Aug; 106 Suppl 1(Suppl 1):179-92. PubMed ID: 21881773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium vivax vaccine research - we've only just begun.
    Tham WH; Beeson JG; Rayner JC
    Int J Parasitol; 2017 Feb; 47(2-3):111-118. PubMed ID: 27899329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium vivax pre-erythrocytic vaccines.
    Reyes-Sandoval A
    Parasitol Int; 2021 Oct; 84():102411. PubMed ID: 34166786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malaria vaccine clinical trials: what's on the horizon.
    Moreno A; Joyner C
    Curr Opin Immunol; 2015 Aug; 35():98-106. PubMed ID: 26172291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines against malaria: perspectives from Papua New Guinea.
    Mueller I; Genton B; Betuela I; Alpers MP
    Hum Vaccin; 2010 Jan; 6(1):17-20. PubMed ID: 20173407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.
    Tachibana M; Takashima E; Morita M; Sattabongkot J; Ishino T; Culleton R; Torii M; Tsuboi T
    Parasitol Int; 2022 Apr; 87():102525. PubMed ID: 34896614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting on planning Plasmodium vivax vaccine efficacy trials. July 20-21, 2004, Singapore.
    Moorthy V; Dubovsky F
    Expert Rev Vaccines; 2006 Feb; 5(1):21-5. PubMed ID: 16451104
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.
    Mueller I; Moorthy VS; Brown GV; Smith PG; Alonso P; Genton B;
    Vaccine; 2009 Sep; 27(41):5633-43. PubMed ID: 19638270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vaccines for Plasmodium vivax malaria.
    Mueller I; Shakri AR; Chitnis CE
    Vaccine; 2015 Dec; 33(52):7489-95. PubMed ID: 26428453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
    Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development.
    Asali S; Raz A; Turki H; Mafakher L; Razmjou E; Solaymani-Mohammadi S
    Infect Genet Evol; 2021 Apr; 89():104710. PubMed ID: 33421653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a plasmid DNA vaccine encoding 42kDa fragment of Plasmodium vivax merozoite surface protein-1.
    Sheikh IH; Kaushal DC; Chandra D; Kaushal NA
    Acta Trop; 2016 Oct; 162():66-74. PubMed ID: 27311385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
    Fonseca JA; McCaffery JN; Caceres J; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
    Vaccine; 2018 May; 36(20):2799-2808. PubMed ID: 29657070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.
    Mueller I; Galinski MR; Baird JK; Carlton JM; Kochar DK; Alonso PL; del Portillo HA
    Lancet Infect Dis; 2009 Sep; 9(9):555-66. PubMed ID: 19695492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.